ProMIS Neurosciences Inc. filings document a clinical-stage biotechnology issuer with common shares listed on the Nasdaq Capital Market and organized in Ontario, Canada. Formal disclosures cover PMN310 and related clinical or regulatory updates, operating results, financing arrangements, registered security status, and the company’s capital structure, including common shares, purchase warrants, pre-funded warrants, and share consolidation actions.
Proxy and 8-K filings record shareholder voting matters, director elections, independent auditor ratification, equity incentive plan proposals, board appointments, and other governance changes. The filing record also documents Nasdaq listing compliance matters, material definitive agreements, and financial condition disclosures connected to the company’s neurodegenerative-disease development programs.
ProMIS Neurosciences Inc. files a Form S-3 to register 13,830,592 Common Shares for resale by certain purchasers from a January 29, 2026 private placement.
The registration covers (i) 6,815,296 Common Shares sold in the private placement, (ii) 6,915,296 Common Shares issuable upon exercise of Common Share Warrants, and (iii) 100,000 Common Shares issuable upon exercise of Pre-Funded Warrants. The company will not receive proceeds from resale by the Selling Securityholders, though it will receive proceeds from any warrant exercises for cash.
ProMIS Neurosciences reports that Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. beneficially owns 895,877 shares of Common Stock, representing 9.99% of the outstanding common shares.
That 895,877 figure comprises 696,378 shares held directly and 199,499 shares issuable upon warrants; an issuance limitation on certain warrants prevents exercise that would result in ownership above 9.99%. The filing bases percentages on approximately 8,967,740 shares outstanding, reflecting a one-for-twenty-five reverse split effective November 28, 2025 and shares reported as issued as of February 3, 2026.
ProMIS Neurosciences Inc. director Williams Eugene reported an open-market purchase of company stock. He bought 2,000 Common Shares at a price of $24.40 per share, increasing his direct holdings to 12,397 Common Shares following the transaction.
ProMIS Neurosciences Inc. director Williams Eugene purchased a total of 4,000 Common Shares in open-market transactions over three days. He bought 1,000 shares at $22.53, 1,000 shares at $21.89, and 2,000 shares at $24.00. Following these purchases, he owns 10,397 Common Shares directly.
ProMIS Neurosciences Inc. received an initial ownership report from Ally Bridge–related investment entities that are ten percent owners. The filing shows indirect holdings of 943,090 Common Shares and 700,741 Warrants. The Warrants are exercisable immediately and will expire on the earlier of within 60 days of a defined Milestone Event or February 3, 2031.
The Milestone Event is the public announcement, via press release or a Form 8-K filing, of topline data from cohorts treated with single ascending doses of PMN310. The Common Shares and Warrants are held of record by Ally Bridge MedAlpha Master Fund L.P., ABG V-SIV IX Limited and ABG V-SIV X Limited, with various Ally Bridge entities and an individual able to be deemed to share beneficial ownership.
ProMIS Neurosciences Inc. Chief Development Officer Johanne Kaplan bought 1,629 common shares in an open-market purchase at $15.35 per share. After this transaction, Kaplan directly owns 3,941 common shares, modestly increasing personal equity exposure to the company.
PROMIS NEUROSCIENCES INC. has a Schedule 13G/A reporting that Armistice Capital, LLC and Steven Boyd beneficially own 504,672 common shares, representing 0.93% of the class. The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., exercises voting and investment power over the shares held by the Master Fund; the Master Fund is the direct holder and disclaims beneficial ownership by virtue of the Investment Management Agreement.
The Schedule is a joint filing by Armistice Capital and Steven Boyd executed 02/17/2026 and lists shared voting and dispositive power consistent with the reported position.
ProMIS Neurosciences Inc. received an updated ownership report showing that Great Point Partners, LLC, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl beneficially own 409,648 common shares, representing 9.99% of the outstanding class.
The filing explains that this stake includes 238,894 common shares issuable upon exercise of various warrants, which are subject to a 9.99% Beneficial Ownership Cap that limits how many shares can be exercised. The report details warrants held through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd. and notes that Great Point, Dr. Jay and Ms. Nordahl may be deemed beneficial owners through their roles, while they disclaim beneficial ownership beyond their pecuniary interests. The reporting group certifies the securities are not held to change or influence control of ProMIS.
ProMIS Neurosciences Inc. disclosed that investment entities affiliated with Trails Edge Capital Partners and Ortav Yehudai have filed a Schedule 13G reporting a 9.9% beneficial stake in its common shares as of February 3, 2026.
The filing shows beneficial ownership of 933,477 shares, consisting of 557,103 common shares and 376,374 shares underlying warrants, held through Trails Edge Biotechnology Master Fund. An additional 180,729 warrant shares are excluded due to a 9.99% ownership cap. Ownership percentages are based on 8,967,740 ProMIS common shares outstanding. The filers certify the holdings are not for changing or influencing control.
ProMIS Neurosciences Inc. received a Schedule 13G filing showing that Deep Track Capital and related entities beneficially own 902,561 common shares, representing 9.99% of the company’s common stock as of February 6, 2026.
The filing explains that this percentage is calculated using 9,034,646 common shares, combining 2,152,444 shares outstanding as of November 12, 2025, 6,815,296 shares issued on January 30, 2026, and 66,906 shares that could be converted up to a 9.99% maximum ownership cap.
The beneficial ownership includes 835,655 warrants that are exercisable into common shares but are subject to a 9.99% “Maximum Percentage” limitation, so exercises cannot push Deep Track’s collective holdings above that threshold.